316 related articles for article (PubMed ID: 28914120)
1. The furthest left behind: the urgent need to scale up harm reduction in prisons.
Sander G; Murphy F
Int J Prison Health; 2017 Sep; 13(3-4):185-191. PubMed ID: 28914120
[TBL] [Abstract][Full Text] [Related]
2. The Global State of Harm Reduction in Prisons.
Sander G; Shirley-Beavan S; Stone K
J Correct Health Care; 2019 Apr; 25(2):105-120. PubMed ID: 31084277
[TBL] [Abstract][Full Text] [Related]
3. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries.
Bielen R; Stumo SR; Halford R; Werling K; Reic T; Stöver H; Robaeys G; Lazarus JV
Harm Reduct J; 2018 May; 15(1):25. PubMed ID: 29751763
[TBL] [Abstract][Full Text] [Related]
4. Reviewing harm reduction for people who inject drugs in Asia: the necessity for growth.
Stone KA
Harm Reduct J; 2015 Oct; 12():32. PubMed ID: 26472335
[TBL] [Abstract][Full Text] [Related]
5. Access to harm reduction and HIV-related treatment services inside Indian prisons: experiences of formerly incarcerated injecting drug users.
Chakrapani V; Kamei R; Kipgen H; Kh JK
Int J Prison Health; 2013; 9(2):82-91. PubMed ID: 25758440
[TBL] [Abstract][Full Text] [Related]
6. Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs.
Day E; Broder T; Bruneau J; Cruse S; Dickie M; Fish S; Grillon C; Luhmann N; Mason K; McLean E; Trooskin S; Treloar C; Grebely J
Int J Drug Policy; 2019 Apr; 66():87-93. PubMed ID: 30743093
[TBL] [Abstract][Full Text] [Related]
7. Drug injection within prison in Kyrgyzstan: elevated HIV risk and implications for scaling up opioid agonist treatments.
Azbel L; Wegman MP; Polonsky M; Bachireddy C; Meyer J; Shumskaya N; Kurmanalieva A; Dvoryak S; Altice FL
Int J Prison Health; 2018 Sep; 14(3):175-187. PubMed ID: 30274558
[TBL] [Abstract][Full Text] [Related]
8. Overview of harm reduction in prisons in seven European countries.
Sander G; Scandurra A; Kamenska A; MacNamara C; Kalpaki C; Bessa CF; Laso GN; Parisi G; Varley L; Wolny M; Moudatsou M; Pontes NH; Mannix-McNamara P; Libianchi S; Antypas T
Harm Reduct J; 2016 Oct; 13(1):28. PubMed ID: 27717368
[TBL] [Abstract][Full Text] [Related]
9. Prisoners who inject drugs: public health and human rights imperatives.
Jürgens R; Betteridge G
Health Hum Rights; 2005; 8(2):46-74. PubMed ID: 17136903
[TBL] [Abstract][Full Text] [Related]
10. UNODC and the National Administration of Penitentiaries launched harm reduction programme in Romanian prisons.
Iliuta C
Int J Prison Health; 2009; 5(1):52-3. PubMed ID: 25758930
[TBL] [Abstract][Full Text] [Related]
11. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
12. The politics of harm reduction in federal prisons.
Watson TM
Int J Drug Policy; 2014 Sep; 25(5):916-23. PubMed ID: 25018152
[TBL] [Abstract][Full Text] [Related]
13. Substitution treatment and HCV/HIV-infection in a sample of 31 German prisons for sentenced inmates.
Schulte B; Stöver H; Thane K; Schreiter C; Gansefort D; Reimer J
Int J Prison Health; 2009; 5(1):39-44. PubMed ID: 25758928
[TBL] [Abstract][Full Text] [Related]
14. Monitoring harm reduction in European prisons via the Dublin Declaration.
Lines R; Stöver H; Donochoe MC; Lazarus JV
Int J Prison Health; 2009; 5(4):251-5. PubMed ID: 25757526
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of harm reduction.
Wilson DP; Donald B; Shattock AJ; Wilson D; Fraser-Hurt N
Int J Drug Policy; 2015 Feb; 26 Suppl 1():S5-11. PubMed ID: 25727260
[TBL] [Abstract][Full Text] [Related]
16. Effects of combination approach on harm reduction programs: the Taiwan experience.
Lin T; Chen CH; Chou P
Harm Reduct J; 2016 Jul; 13(1):23. PubMed ID: 27377896
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
[TBL] [Abstract][Full Text] [Related]
18. A Senior Management Perspective on the Policy Debate of Needle and Syringe Exchange Program Provision in Irish Prisons.
Rosalim JP
J Correct Health Care; 2020 Jan; 26(1):27-35. PubMed ID: 31983260
[TBL] [Abstract][Full Text] [Related]
19. A harm reduction paradox: comparing China's policies on needle and syringe exchange and methadone maintenance.
Smith K; Bartlett N; Wang N
Int J Drug Policy; 2012 Jul; 23(4):327-32. PubMed ID: 22377341
[TBL] [Abstract][Full Text] [Related]
20. The state of harm reduction in prisons in 30 European countries with a focus on people who inject drugs and infectious diseases.
Stöver H; Tarján A; Horváth G; Montanari L
Harm Reduct J; 2021 Jun; 18(1):67. PubMed ID: 34187471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
